This study has several limitations: first, the small sample size, even though it is a single-center study; second, the scarce literature on this topic did not allow the definition of specific outcomes for assessing any intervention on lymphedema in T2DM; third, the lack of data on glycosylated albumin that could be useful as an indicator of glycemic control. The gene discussed is ALB; the disease is lymphedema.